On December 17, Glonghui announced that CARDIOFLOW-B (02160.HK) has received registration approval from the China National Medical Products Administration for its self-developed third-generation transcatheter aortic valve implantation (TAVI) product, the VitaFlow LibertyFlex transcatheter aortic valve recoverable controllable bending delivery system ("VitaFlow LibertyFlex").

VitaFlow LibertyFlex is an upgraded version of the VitaFlow Liberty delivery system and can be used in conjunction with the aortic valve that has already been approved by the group. It inherits all the advantages of the VitaFlow Liberty delivery system and innovatively adds a 3D spatial bending function. Its unique internal tube bending technology allows the valve to remain coaxial during the release process, making the implantation more stable and precise, as well as smoother and safer across the arch and the valve. At the same time, VitaFlow LibertyFlex achieves interface alignment of the valve release, protecting the coronary pathway and reserving space for future coronary interventions. This product provides doctors with a superior ease of use experience, further enhancing surgical efficiency and safety, while reducing the incidence of surgical complications. In addition, thanks to the company's full lifecycle management concept deeply practiced during the R&D phase, VitaFlow LibertyFlex will help the company further reduce production costs.